SCHEMBL4537589

SCHEMBL4537589

CC(C)OC(=O)[C@@H](N)CCC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 2/20 0.54
GABRD O14764 2/20 0.54
GABRA1 P14867 2/20 0.54
GABRB1 P18505 2/20 0.54
GABRG2 P18507 2/20 0.54
GABRB3 P28472 2/20 0.54
GABRA5 P31644 2/20 0.54
GABRA3 P34903 2/20 0.54
GABRA2 P47869 2/20 0.54
GABRB2 P47870 2/20 0.54
GABRA4 P48169 2/20 0.54
GABRE P78334 2/20 0.54
GABRA6 Q16445 2/20 0.54
GABRG1 Q8N1C3 2/20 0.54
GABRG3 Q99928 2/20 0.54
GABRQ Q9UN88 2/20 0.54
CYP1A2 P05177 2/20 0.54
GRM8 O00222 1/20 0.54
GRM6 O15303 1/20 0.54
GRIN2D O15399 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7780572 1.00 GABRP (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2241803 0.84 LMNA (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5964545 0.84 ALOX15 (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4537585 0.84 LMNA (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL28096046 0.84 LMNA (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL7775146 0.84 ALOX15 (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL23408823 0.83 GABRP (0.48) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4379768 0.83 GABRP (0.48) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1767320 0.82 CYP1A2 (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL10874134 0.82 GABRP (0.47) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117017830-A Solubilizing composition and use thereof 华熙生物科技股份有限公司 2023-11-10 CN disclosed
US-8084499-B2 Modified clay mineral AJINOMOTO CO., INC. (JP) 2011-12-27 US disclosed
US-20090098169-A1 MODIFIED CLAY MINERAL AJINOMOTO CO., INC (JP) 2009-04-16 US disclosed
EP-1135398-A1 CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION Monsanto Technology LLC (US) 2001-09-26 EP disclosed
US-6218563-B1 Cyanophosphonamides and method for preparation MONSANTO COMPANY 2001-04-17 US disclosed
WO-2000032611-A1 CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION MONSANTO TECHNOLOGY LLC (US) 2000-06-08 WO disclosed
EP-0572167-B1 Cosmetic composition UNILEVER PLC (GB) 1996-10-09 EP disclosed
EP-0572167-A1 Cosmestic composition UNILEVER PLC (GB) 1993-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090098169-A1 MODIFIED CLAY MINERAL CUTA, ARG1, AS3MT GABRP 4328/4885GABRD 4736/4885GABRA1 4482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.